Erratum: The International/Canadian Hereditary Angioedema Guideline (Allergy Asthma Clin Immunol (2020) 16 (33) DOI: 10.1186/s13223-019-0376-8)

Abstract

Following the publication of this article [1], the authors requested to amend the characterisation of lanadelumab from humanised to the correct fully human. Therefore, the fourth paragraph under Recommendation #24 should be amended to read: Lanadelumab (Takeda), a fully human monoclonal antibody against kallikrein, takes approximately 70 days to reach a steady state concentration [110], and is therefore not recommended for STP Similarly, the first paragraph under Recommendation #27 should be amended to read: Lanadelumab is a subcutaneously injectable, fully human, anti-active plasma kallikrein monoclonal antibody (IgG1/K-light chain).